(LEGN) Legend Biotech - Ratings and Ratios
CAR-T, Oncology, Myeloma, Hematologic Malignancies, Solid Tumors
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 55.8% |
| Value at Risk 5%th | 86.6% |
| Relative Tail Risk | -5.59% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.01 |
| Alpha | -51.88 |
| CAGR/Max DD | -0.32 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.568 |
| Beta | 0.512 |
| Beta Downside | 0.379 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.78% |
| Mean DD | 32.77% |
| Median DD | 33.03% |
Description: LEGN Legend Biotech November 05, 2025
Legend Biotech Corp (NASDAQ: LEGN) is a U.S.-based biopharma that discovers, develops, manufactures, and commercializes novel cell-therapy platforms across the United States, China, and Europe. Founded in 2014 and headquartered in Somerset, New Jersey, the firm operates primarily in the biotechnology sub-industry.
The company’s flagship asset is ciltacabtagene autoleucel (cilta-cel), a BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma. Cilta-cel received FDA approval in February 2023 and has since generated $85 million in net product revenue in Q1 2024, reflecting early commercial traction in the U.S. market.
Legend’s pipeline extends beyond cilta-cel to include autologous CAR-T candidates for non-Hodgkin lymphoma, acute lymphoblastic leukemia, gastric, esophageal, pancreatic, colorectal, hepatocellular, small-cell lung, and non-small-cell lung cancers. In parallel, the firm is advancing allogeneic gamma-delta CAR-T and CAR-NK programs targeting BCMA in Phase 1 investigator-initiated trials in China. Strategic partnerships amplify development and commercialization reach: a collaboration with Janssen Biotech on cilta-cel and a licensing deal with Novartis for delta-like ligand 3-targeted CAR-T therapies.
From a market perspective, the global CAR-T sector is projected to grow at a compound annual growth rate of roughly 20 % through 2030, driven by expanding indications and reimbursement pathways; multiple myeloma alone represents a $13 billion addressable market in the U.S. As of the latest filing, Legend holds approximately $310 million in cash and short-term investments, providing runway for continued R&D and potential geographic expansion. For a deeper, data-driven valuation of LEG N, the ValueRay platform offers granular cash-flow models and scenario analysis you can explore at your own pace.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-239.7m TTM) > 0 and > 6% of Revenue (6% = 54.5m TTM) |
| FCFTA -0.11 (>2.0%) and ΔFCFTA -0.87pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 88.94% (prev 207.5%; Δ -118.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.10 (>3.0%) and CFO -170.1m > Net Income -239.7m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (92.3m) change vs 12m ago 1.05% (target <= -2.0% for YES) |
| Gross Margin 60.55% (prev 62.88%; Δ -2.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 52.71% (prev 29.97%; Δ 22.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -9.81 (EBITDA TTM -183.3m / Interest Expense TTM 21.1m) >= 6 (WARN >= 3) |
Altman Z'' -3.96
| (A) 0.47 = (Total Current Assets 1.24b - Total Current Liabilities 433.6m) / Total Assets 1.71b |
| (B) -1.13 = Retained Earnings (Balance) -1.93b / Total Assets 1.71b |
| warn (B) unusual magnitude: -1.13 — check mapping/units |
| (C) -0.12 = EBIT TTM -207.1m / Avg Total Assets 1.72b |
| (D) -2.46 = Book Value of Equity -1.73b / Total Liabilities 701.7m |
| Total Rating: -3.96 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.96
| 1. Piotroski 1.50pt |
| 2. FCF Yield -4.20% |
| 3. FCF Margin -20.76% |
| 4. Debt/Equity 0.41 |
| 5. Debt/Ebitda -0.72 |
| 6. ROIC - WACC (= -23.18)% |
| 7. RoE -23.36% |
| 8. Rev. Trend 87.61% |
| 9. EPS Trend 11.32% |
What is the price of LEGN shares?
Over the past week, the price has changed by -10.53%, over one month by -24.41%, over three months by -30.28% and over the past year by -42.64%.
Is LEGN a buy, sell or hold?
- Strong Buy: 11
- Buy: 10
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the LEGN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 74.9 | 213.7% |
| Analysts Target Price | 74.9 | 213.7% |
| ValueRay Target Price | 23.1 | -3.1% |
LEGN Fundamental Data Overview November 29, 2025
P/E Forward = 80.6452
P/S = 5.5871
P/B = 5.0224
Beta = 0.074
Revenue TTM = 909.0m USD
EBIT TTM = -207.1m USD
EBITDA TTM = -183.3m USD
Long Term Debt = 171.9m USD (from longTermDebt, last quarter)
Short Term Debt = 150.2m USD (from shortTermDebt, last quarter)
Debt = 410.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 131.3m USD (from netDebt column, last quarter)
Enterprise Value = 4.50b USD (5.08b + Debt 410.2m - CCE 992.6m)
Interest Coverage Ratio = -9.81 (Ebit TTM -207.1m / Interest Expense TTM 21.1m)
FCF Yield = -4.20% (FCF TTM -188.7m / Enterprise Value 4.50b)
FCF Margin = -20.76% (FCF TTM -188.7m / Revenue TTM 909.0m)
Net Margin = -26.37% (Net Income TTM -239.7m / Revenue TTM 909.0m)
Gross Margin = 60.55% ((Revenue TTM 909.0m - Cost of Revenue TTM 358.6m) / Revenue TTM)
Gross Margin QoQ = 57.66% (prev 61.58%)
Tobins Q-Ratio = 2.63 (Enterprise Value 4.50b / Total Assets 1.71b)
Interest Expense / Debt = 1.38% (Interest Expense 5.64m / Debt 410.2m)
Taxrate = -1.58% (negative due to tax credits) (616.0k / -39.1m)
NOPAT = -210.3m (EBIT -207.1m * (1 - -1.58%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.86 (Total Current Assets 1.24b / Total Current Liabilities 433.6m)
Debt / Equity = 0.41 (Debt 410.2m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = -0.72 (negative EBITDA) (Net Debt 131.3m / EBITDA -183.3m)
Debt / FCF = -0.70 (negative FCF - burning cash) (Net Debt 131.3m / FCF TTM -188.7m)
Total Stockholder Equity = 1.03b (last 4 quarters mean from totalStockholderEquity)
RoA = -13.99% (Net Income -239.7m / Total Assets 1.71b)
RoE = -23.36% (Net Income TTM -239.7m / Total Stockholder Equity 1.03b)
RoCE = -17.28% (EBIT -207.1m / Capital Employed (Equity 1.03b + L.T.Debt 171.9m))
RoIC = -15.76% (negative operating profit) (NOPAT -210.3m / Invested Capital 1.33b)
WACC = 7.41% (E(5.08b)/V(5.49b) * Re(7.90%) + D(410.2m)/V(5.49b) * Rd(1.38%) * (1-Tc(-0.02)))
Discount Rate = 7.90% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.75%
Fair Price DCF = unknown (Cash Flow -188.7m)
EPS Correlation: 11.32 | EPS CAGR: 5.38% | SUE: -0.18 | # QB: 0
Revenue Correlation: 87.61 | Revenue CAGR: 67.92% | SUE: -0.09 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=N/A | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=0.54 | Chg30d=+0.046 | Revisions Net=-3 | Growth EPS=+164.0% | Growth Revenue=+51.1%
Additional Sources for LEGN Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle